{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:34:48Z","timestamp":1787924088546,"version":"build-2784847793"},"reference-count":100,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Purpose: This review aims to provide an updated overview of Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations in colorectal carcinoma (CRC), focusing on their role in tumorigenesis, prognostic implications, and recent advances in targeted therapy. Major findings: KRAS mutations occur in approximately 40% of colorectal cancers and play a central role in tumour initiation and progression through constitutive activation of MAPK pathways. Clinically, KRAS mutations are well established as predictors of resistance to anti-EGFR therapy. Increasing evidence also supports their role as prognostic biomarkers, with KRAS-mutant tumours associated with increased recurrence risk and reduced survival, including in patients undergoing hepatic metastasectomy. Therapeutically, recent advances, most notably KRAS G12C inhibitors and combination strategies targeting upstream or parallel pathways, have expanded treatment options, although efficacy varies across KRAS mutation subtypes. Conclusions: KRAS mutations have important implications for the behaviour, prognosis, and management of colorectal cancer. Integrating KRAS mutational status into clinical decision-making may enable more personalised prognostication and treatment strategies. Continued research is required to broaden effective targeted therapies for the diverse spectrum of KRAS-mutant disease.<\/jats:p>","DOI":"10.3390\/curroncol33090514","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:27:46Z","timestamp":1787920066000},"page":"514","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["KRAS in Colorectal Cancer: Tumorigenesis, Surgical Implications and Evolving Treatment Target"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5947-4136","authenticated-orcid":false,"given":"Sahar","family":"Iftikhar","sequence":"first","affiliation":[{"name":"School of Medicine, Medical Sciences, and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8929-9798","authenticated-orcid":false,"given":"Alexander H.","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7844-5833","authenticated-orcid":false,"given":"Zhaohui","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad H.","family":"Aly","sequence":"additional","affiliation":[{"name":"School of Medicine, Medical Sciences, and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK"},{"name":"Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"ref_1","first-page":"e70090","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Zhang, X., Fan, H., Han, S., Zhang, T., Sun, Y., Yang, L., and Li, W. (2025). Global burden of colon and rectal cancer and attributable risk factors in 204 countries and territories from 1990 to 2021. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-03948-2"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/gastro\/goab010","article-title":"Gastrointestinal cancers in China, the USA, and Europe","volume":"9","author":"Xie","year":"2021","journal-title":"Gastroenterol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(24)00600-4","article-title":"Colorectal cancer incidence trends in younger versus older adults: An analysis of population-based cancer registry data","volume":"26","author":"Sung","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Thanikachalam, K., and Khan, G. (2019). Colorectal Cancer and Nutrition. Nutrients, 11.","DOI":"10.3390\/nu11010164"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.gastro.2019.08.059","article-title":"Pathways of Colorectal Carcinogenesis","volume":"158","author":"Nguyen","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_7","unstructured":"Wild, C.P., Weiderpass, E., and Stewart, B.W. (2020). Colorectal cancer: Decreasing disparities and promoting prevention are policy priorities. World Cancer Report: Cancer Research for Cancer Prevention, International Agency for Research on Cancer."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13073-016-0387-8","article-title":"Genomic landscape of colorectal cancer in Japan: Clinical implications of comprehensive genomic sequencing for precision medicine","volume":"8","author":"Nagahashi","year":"2016","journal-title":"Genome Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12967-017-1353-y","article-title":"Next-generation sequencing: Recent applications to the analysis of colorectal cancer","volume":"15","author":"Mastroiaco","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.gastro.2022.08.058","article-title":"Lynch Syndrome Genetics and Clinical Implications","volume":"164","author":"Mecklin","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.5858\/arpa.2018-0570-RA","article-title":"Familial Adenomatous Polyposis Syndrome: An Update and Review of Extraintestinal Manifestations","volume":"143","author":"Dinarvand","year":"2019","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/gastro\/goaa022","article-title":"BRAF and KRAS mutations in metastatic colorectal cancer: Future perspectives for personalized therapy","volume":"8","author":"Li","year":"2020","journal-title":"Gastroenterol. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","article-title":"Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer","volume":"20","author":"Zhu","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","article-title":"Molecular epidemiology and diagnostics of KRAS mutations in human cancer","volume":"39","author":"Timar","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., and Yamamoto, H. (2025). The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives. Cancers, 17.","DOI":"10.3390\/cancers17030428"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","article-title":"ERK signalling: A master regulator of cell behaviour, life and fate","volume":"21","author":"Lavoie","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins and Their Regulators in Human Disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Poorebrahim, M., Abazari, M.F., Moradi, L., Shahbazi, B., Mahmoudi, R., Kalhor, H., Askari, H., and Teimoori-Toolabi, L. (2022). Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors. PLoS Comput. Biol., 18.","DOI":"10.1371\/journal.pcbi.1009962"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/1078-0432.CCR-17-2484","article-title":"Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes","volume":"24","author":"Loree","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102343","DOI":"10.1016\/j.coph.2022.102343","article-title":"KRAS inhibition in metastatic colorectal cancer: An update","volume":"68","author":"Nusrat","year":"2023","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Tria, S.M., Burge, M.E., and Whitehall, V.L.J. (2023). The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers. Cancers, 15.","DOI":"10.3390\/cancers15082375"},{"key":"ref_22","first-page":"23","article-title":"KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model","volume":"7","author":"Kumar","year":"2014","journal-title":"Gastrointest. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1158\/1078-0432.CCR-19-2390","article-title":"Coaltered Ras\/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer","volume":"26","author":"Datta","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","article-title":"A genetic model for colorectal tumorigenesis","volume":"61","author":"Fearon","year":"1990","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"20681","DOI":"10.1073\/pnas.2003771117","article-title":"Mathematical model of colorectal cancer initiation","volume":"117","author":"Paterson","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1038\/s41598-020-59899-z","article-title":"APC controls Wnt-induced \u03b2-catenin destruction complex recruitment in human colonocytes","volume":"10","author":"Parker","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.biochi.2022.01.009","article-title":"Wnt\/\u03b2-catenin signaling in colorectal cancer: Is therapeutic targeting even possible?","volume":"195","author":"Disoma","year":"2022","journal-title":"Biochimie"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00428-016-1956-3","article-title":"Molecular pathological classification of colorectal cancer","volume":"469","author":"Ibrahim","year":"2016","journal-title":"Virchows Arch."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Mamlouk, S., Simon, T., Tom\u00e1s, L., Wedge, D.C., Arnold, A., Menne, A., Horst, D., Capper, D., Morkel, M., and Posada, D. (2020). Malignant transformation and genetic alterations are uncoupled in early colorectal cancer progression. BMC Biol., 18.","DOI":"10.1186\/s12915-020-00844-x"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Michel, M., Kaps, L., Maderer, A., Galle, P.R., and Moehler, M. (2021). The role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. Cancers, 13.","DOI":"10.3390\/cancers13102296"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","article-title":"Therapeutic targeting of p53: All mutants are equal, but some mutants are more equal than others","volume":"15","author":"Sabapathy","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"a026104","DOI":"10.1101\/cshperspect.a026104","article-title":"The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression","volume":"6","author":"Chen","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"272","DOI":"10.31083\/j.fbl2907272","article-title":"Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant","volume":"29","author":"Li","year":"2024","journal-title":"Front. Biosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1186\/s12967-025-06566-4","article-title":"p53 in colorectal cancer: From a master player to a privileged therapy target","volume":"23","author":"Yan","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.giec.2021.12.001","article-title":"Cause, Epidemiology, and Histology of Polyps and Pathways to Colorectal Cancer","volume":"32","author":"Sullivan","year":"2022","journal-title":"Gastrointest. Endosc. Clin. N. Am."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"De Palma, F.D.E., D\u2019Argenio, V., Pol, J., Kroemer, G., Maiuri, M.C., and Salvatore, F. (2019). The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer. Cancers, 11.","DOI":"10.3390\/cancers11071017"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcmgh.2022.10.001","article-title":"Single-cell Transcriptomics Reveals Early Molecular and Immune Alterations Underlying the Serrated Neoplasia Pathway Toward Colorectal Cancer","volume":"15","author":"Zhou","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e000317","DOI":"10.1136\/bmjgast-2019-000317","article-title":"Traditional serrated adenoma: An overview of pathology and emphasis on molecular pathogenesis","volume":"6","author":"McCarthy","year":"2019","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"155786","DOI":"10.1016\/j.prp.2024.155786","article-title":"MLH1 gene promoter methylation status partially overlaps with CpG methylator phenotype (CIMP) in colorectal adenocarcinoma","volume":"266","author":"Ceccon","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"103647","DOI":"10.1016\/j.critrevonc.2022.103647","article-title":"BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications","volume":"172","author":"Angerilli","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5009\/gnl19402","article-title":"Molecular Features of the Serrated Pathway to Colorectal Cancer: Current Knowledge and Future Directions","volume":"15","author":"Satorres","year":"2021","journal-title":"Gut Liver"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Mezzapesa, M., Losurdo, G., Celiberto, F., Rizzi, S., D\u2019Amati, A., Piscitelli, D., Ierardi, E., and Di Leo, A. (2022). Serrated Colorectal Lesions: An Up-to-Date Review from Histological Pattern to Molecular Pathogenesis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084461"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/cas.16160","article-title":"Microsatellite instability: A 2024 update","volume":"115","author":"Yamamoto","year":"2024","journal-title":"Cancer Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Shiu","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e516576","DOI":"10.1200\/EDBK-26-516576","article-title":"Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics","volume":"46","author":"Grochot","year":"2026","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Parseghian, C., Eluri, M., Kopetz, S., and Raghav, K. (2023). Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: More than just genetics. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1176657"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Diaz","year":"2012","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"13665","DOI":"10.1038\/ncomms13665","article-title":"Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer","volume":"7","author":"Arena","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"19607","DOI":"10.1038\/s41598-025-03684-3","article-title":"Retrospective stratified analysis of resistance mechanisms to anti-EGFR therapy in mCRC using tumor tissue samples","volume":"15","author":"Xia","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13046-019-1035-0","article-title":"Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR\/RAS\/MAPK pathway in KRAS-mutated human colorectal cancer cell lines","volume":"38","author":"Vitiello","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccell.2025.10.010","article-title":"Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer","volume":"44","author":"Zhang","year":"2026","journal-title":"Cancer Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"102417","DOI":"10.1016\/j.clinre.2024.102417","article-title":"Liquid biopsy as a tool for KRAS\/NRAS\/BRAF baseline testing in metastatic colorectal cancer","volume":"48","author":"Kourie","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"105180","DOI":"10.1016\/j.critrevonc.2026.105180","article-title":"Anti-EGFR rechallenge compared with standard of care for patients with ctDNA RAS\/BRAF wild-type chemorefractory metastatic colorectal cancer: A systematic review and meta-analysis","volume":"220","author":"Kuznetsova","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1186\/s12967-025-06710-0","article-title":"Performance of KRAS mutation detection in plasma exosomes from patients with early-stage colorectal cancer","volume":"23","author":"Nouri","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Ottaiano, A., Penta de Vera d\u2019Aragona, R., Trotta, A.M., Santorsola, M., Napolitano, M., Scognamiglio, G., Tatangelo, F., Grieco, P., Zappavigna, S., and Granata, V. (2022). Characterization of KRAS Mutational Regression in Oligometastatic Patients. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.898561"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Ottaiano, A., Normanno, N., Facchini, S., Cassata, A., Nappi, A., Romano, C., Silvestro, L., De Stefano, A., Rachiglio, A.M., and Roma, C. (2020). Study of Ras Mutations\u2019 Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis. Cancers, 12.","DOI":"10.3390\/cancers12071919"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.molonc.2016.10.001","article-title":"Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases","volume":"10","author":"Beije","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41598-020-79909-4","article-title":"Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer","volume":"11","author":"Nakamura","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1002\/cncr.28954","article-title":"KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases","volume":"120","author":"Kemeny","year":"2014","journal-title":"Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41416-020-01169-w","article-title":"The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients","volume":"124","author":"Vreeland","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1002371","DOI":"10.37349\/etat.2026.1002371","article-title":"Oligometastatic versus polymetastatic colon cancer: Functional and genomic determinants of divergent metastatic trajectories","volume":"7","author":"Sirica","year":"2026","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"101111","DOI":"10.1016\/j.neo.2024.101111","article-title":"Clinical and genetic drivers of oligo-metastatic disease in colon cancer","volume":"60","author":"Ottaiano","year":"2025","journal-title":"Neoplasia"},{"key":"ref_64","first-page":"164","article-title":"The heterogeneity of KRAS mutations in colorectal cancer and its biomarker implications: An ever-evolving story","volume":"2","author":"Sahin","year":"2013","journal-title":"Transl. Gastrointest. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.aam7622","article-title":"Drugging RAS: Know the enemy","volume":"355","author":"Papke","year":"2017","journal-title":"Science"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: From undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Ros, J., Vaghi, C., Baraibar, I., Saoudi Gonz\u00e1lez, N., Rodr\u00edguez-Castells, M., Garc\u00eda, A., Alcaraz, A., Salva, F., Tabernero, J., and Elez, E. (2024). Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063304"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3892\/mco.2025.2873","article-title":"Targeting KRAS in colorectal cancer (Review)","volume":"23","author":"Zhang","year":"2025","journal-title":"Mol. Clin. Oncol."},{"key":"ref_69","first-page":"e247067","article-title":"Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer","volume":"23","author":"Deming","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR Blockade Reverts Resistance to KRAS G12C Inhibition in Colorectal Cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/s43018-024-00800-6","article-title":"Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance","volume":"5","author":"Thatikonda","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40164-025-00637-4","article-title":"New exploration of KRASG12D inhibitors and the mechanisms of resistance","volume":"14","author":"Li","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2026.44.2_suppl.654","article-title":"Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced\/metastatic pancreatic ductal adenocarcinoma (PDAC)","volume":"44","author":"Wainberg","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.2026.44.2_suppl.704","article-title":"Efficacy and safety of ASP3082 monotherapy or in combination with mFOLFIRINOX in patients with pancreatic ductal adenocarcinoma (PDAC)","volume":"44","author":"Kasi","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.ccell.2025.05.016","article-title":"A first-in-class EGFR-directed KRAS G12V selective inhibitor","volume":"43","author":"Stanland","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tips.2025.07.004","article-title":"EFTX-G12V: A novel KRASG12V-selective RNAi therapeutic","volume":"46","author":"Papavassiliou","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"B137","DOI":"10.1158\/1535-7163.TARG-23-B137","article-title":"Selective inhibition of the active state of KRASG12V with the non-covalent, tri-complex inhibitor RM-048","volume":"22","author":"Lee","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_79","unstructured":"(2025, August 26). Patsnap Synapse. VRTX-171 Drug Profile. Available online: https:\/\/synapse.patsnap.com\/drug\/57b47a75708a4394896933682b0b29f6."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12964-020-00645-3","article-title":"Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors","volume":"18","author":"McFall","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.7150\/thno.97180","article-title":"Honokiol enhances the sensitivity of cetuximab in KRASG13D mutant colorectal cancer through destroying SNX3-retromer complex","volume":"14","author":"Zhu","year":"2024","journal-title":"Theranostics"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12943-025-02343-5","article-title":"Targeting the HER2-ELF3-KRAS axis: A novel therapeutic strategy for KRASG13D colorectal cancer","volume":"24","author":"Hwang","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7554","DOI":"10.1038\/s41467-024-51828-2","article-title":"RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade","volume":"15","author":"Nokin","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","article-title":"Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer","volume":"394","author":"Wolpin","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"108226","DOI":"10.1016\/j.phrs.2026.108226","article-title":"Daraxonrasib (RMC-6236) pharmacokinetics: Impact of transporters and drug metabolizing enzymes on a first-in-class pan-RAS molecular glue","volume":"229","author":"Arguedas","year":"2026","journal-title":"Pharmacol. Res."},{"key":"ref_86","unstructured":"ClinicalTrials.gov (2026, June 14). Phase 3 Study of Daraxonrasib (RMC-6236) in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06625320."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.cell.2026.03.031","article-title":"Disrupted molecular glue complex drives RAS inhibitor resistance","volume":"189","author":"Sang","year":"2026","journal-title":"Cell"},{"key":"ref_88","unstructured":"ClinicalTrials.gov (2026, June 14). Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05379985."},{"key":"ref_89","unstructured":"ClinicalTrials.gov (2026, June 14). Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06445062."},{"key":"ref_90","unstructured":"ClinicalTrials.gov (2026, June 14). Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants with Advanced KRAS G12C Mutant Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06128551."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1535-7163.MCT-18-0852","article-title":"SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors","volume":"18","author":"Lu","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"107380","DOI":"10.4251\/wjgo.v17.i7.107380","article-title":"Targeting SHP2: Dual breakthroughs in colorectal cancer therapy\u2014From signaling pathway modulation to immune microenvironment remodeling","volume":"17","author":"Liu","year":"2025","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"107886","DOI":"10.1016\/j.lungcan.2024.107886","article-title":"The next-generation KRAS inhibitors\u2026What comes after sotorasib and adagrasib?","volume":"194","author":"Oya","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13046-018-0719-1","article-title":"Targeting KRAS in metastatic colorectal cancer: Current strategies and emerging opportunities","volume":"37","author":"Porru","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO-24-01266","article-title":"Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_97","unstructured":"ClinicalTrials.gov (2025, August 26). Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants with a KRAS or NRAS Mutation, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06106308."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: Phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent. Sci."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/514\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:10:27Z","timestamp":1787922627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":100,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["curroncol33090514"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33090514","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}